{
    "pmcid": "8811630",
    "summary": "The paper titled \"Biparatopic nanobodies protect mice from lethal challenge with SARS\u2010CoV\u20102 variants of concern\" focuses on the development and evaluation of biparatopic nanobodies (bipNbs) as potential therapeutics against SARS-CoV-2 and its variants of concern (VOCs). Here is a detailed summary with a focus on the nanobodies aspect:\n\n### Background and Rationale\n- **COVID-19 Challenges**: The ongoing pandemic, coupled with the emergence of new SARS-CoV-2 variants, necessitates the development of effective therapeutics. Despite vaccines, there are gaps in global immunity, and breakthrough infections can occur, especially in vulnerable populations.\n- **Nanobodies (Nbs)**: These are camelid single-domain antibody fragments known for their small size, stability, and efficient tissue penetration, making them ideal for therapeutic applications. They have shown strong neutralizing efficacy against SARS-CoV-2, particularly in multivalent or biparatopic formats.\n\n### Design and Development of Biparatopic Nanobodies\n- **Biparatopic Nanobodies (bipNbs)**: The study focuses on two bipNbs, NM1267 and NM1268, which target distinct epitopes on the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. NM1267 binds one epitope inside and one outside the RBD:ACE2 interface, while NM1268 targets a different epitope within the interface.\n- **Construction**: These bipNbs were engineered by genetically linking two nanobodies with a flexible Gly-Ser linker, enhancing their binding and neutralization capabilities.\n\n### Biochemical and Biophysical Characterization\n- **Binding Affinity**: Both bipNbs demonstrated high picomolar affinities to the RBDs of various SARS-CoV-2 variants, confirmed through biolayer interferometry.\n- **ACE2 Displacement**: They effectively blocked the interaction between the RBD and human ACE2 receptor, crucial for preventing viral entry.\n- **Stability**: Both bipNbs exhibited high thermal stability and maintained their structural integrity even after accelerated aging, indicating their suitability for therapeutic use.\n\n### In Vitro and In Vivo Efficacy\n- **In Vitro Neutralization**: The bipNbs showed strong neutralizing capacity against SARS-CoV-2 B.1 and VOCs B.1.351 (Beta) and B.1.617.2 (Delta). NM1268, in particular, displayed robust neutralization across all tested variants.\n- **In Vivo Protection**: In transgenic mice expressing human ACE2, prophylactic intranasal administration of NM1267 and NM1268 significantly reduced disease progression and mortality when challenged with lethal doses of SARS-CoV-2 B.1, B.1.351 (Beta), and B.1.617.2 (Delta). Histopathological analyses revealed reduced viral load and inflammation in the lungs of treated mice.\n\n### Implications and Future Directions\n- **Broad Applicability**: The study underscores the potential of bipNbs as broadly applicable drug candidates for preventing or treating SARS-CoV-2 infections, particularly in unvaccinated or immunocompromised individuals.\n- **Therapeutic Strategies**: The biparatopic approach, targeting multiple epitopes, offers a promising strategy to prevent viral escape mutations. Further modifications, such as fusion to Fc-moieties or albumin-binding motifs, could enhance the duration of effectiveness.\n- **Clinical Translation**: Future studies are needed to evaluate the immunogenicity of these bipNbs and their efficacy in more physiological models, such as Syrian hamsters or non-human primates, to better understand their therapeutic potential and safety profile.\n\n### Conclusion\nThis study highlights the successful design and application of biparatopic nanobodies against SARS-CoV-2 and its variants, demonstrating their potential as effective therapeutics. The rational design based on detailed epitope mapping and binding properties provides a framework for developing robust antiviral agents in the face of emerging viral threats.",
    "title": "Biparatopic nanobodies protect mice from lethal challenge with SARS\u2010CoV\u20102 variants of concern"
}